Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > December 9, 2022
Daily News
December 9, 2022
- Berinert SC Injection Holds Promise as “First Choice” for HAE Attacks: CSL Japan Chief
December 9, 2022
- CSL to Bring 1st Hemophilia B Gene Therapy to Japan Too; Eyes Riveted on Price Tag
December 9, 2022
- Merck CEO Wants to See Japan’s Shift to Pro-Innovation Structure in 2024 Reform
December 9, 2022
- First Generics for 5 APIs Join NHI Price List, Main Targets Are Nexium/Lexapro
December 9, 2022
- Gilead to Take Over Yescarta Marketing Authorization in Japan
December 9, 2022
- Panel OKs Moderna Boosters for Age 12 and Up
December 9, 2022
- UCB Files C5 Inhibitor Zilucoplan for Japan Approval
December 9, 2022
- How to Succeed in Bad Times and Good
December 9, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…